1. Home
  2. PCRX vs OKLO Comparison

PCRX vs OKLO Comparison

Compare PCRX & OKLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PCRX
  • OKLO
  • Stock Information
  • Founded
  • PCRX 2006
  • OKLO 2013
  • Country
  • PCRX United States
  • OKLO United States
  • Employees
  • PCRX N/A
  • OKLO N/A
  • Industry
  • PCRX Biotechnology: Pharmaceutical Preparations
  • OKLO
  • Sector
  • PCRX Health Care
  • OKLO
  • Exchange
  • PCRX Nasdaq
  • OKLO NYSE
  • Market Cap
  • PCRX 1.2B
  • OKLO 9.4B
  • IPO Year
  • PCRX 2011
  • OKLO N/A
  • Fundamental
  • Price
  • PCRX $23.21
  • OKLO $51.38
  • Analyst Decision
  • PCRX Buy
  • OKLO Strong Buy
  • Analyst Count
  • PCRX 9
  • OKLO 9
  • Target Price
  • PCRX $29.89
  • OKLO $58.14
  • AVG Volume (30 Days)
  • PCRX 582.1K
  • OKLO 21.6M
  • Earning Date
  • PCRX 07-29-2025
  • OKLO 08-12-2025
  • Dividend Yield
  • PCRX N/A
  • OKLO N/A
  • EPS Growth
  • PCRX N/A
  • OKLO N/A
  • EPS
  • PCRX N/A
  • OKLO N/A
  • Revenue
  • PCRX $702,772,000.00
  • OKLO N/A
  • Revenue This Year
  • PCRX $7.54
  • OKLO N/A
  • Revenue Next Year
  • PCRX $10.78
  • OKLO N/A
  • P/E Ratio
  • PCRX N/A
  • OKLO N/A
  • Revenue Growth
  • PCRX 3.08
  • OKLO N/A
  • 52 Week Low
  • PCRX $11.16
  • OKLO $5.35
  • 52 Week High
  • PCRX $29.33
  • OKLO $73.55
  • Technical
  • Relative Strength Index (RSI)
  • PCRX 35.28
  • OKLO 47.86
  • Support Level
  • PCRX $23.24
  • OKLO $55.35
  • Resistance Level
  • PCRX $24.36
  • OKLO $62.10
  • Average True Range (ATR)
  • PCRX 0.74
  • OKLO 5.73
  • MACD
  • PCRX -0.13
  • OKLO -1.93
  • Stochastic Oscillator
  • PCRX 15.58
  • OKLO 5.51

About PCRX Pacira BioSciences Inc.

Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.

About OKLO OKLO INC

Oklo Inc is developing advanced fission power plants to provide clean, reliable, and affordable energy at scale. It is pursuing two complementary tracks to address this demand: providing reliable, commercial-scale energy to customers; and selling used nuclear fuel recycling services to the U.S. market. The Company plans to commercialize its liquid metal fast reactor technology with the Aurora powerhouse product line. The first commercial Aurora powerhouse is designed to produce up to 15 megawatts of electricity (MWe) on both recycled nuclear fuel and fresh fuel.

Share on Social Networks: